

REPROS THERAPEUTICS INC.  
Form 8-K  
August 07, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): August 6, 2009  
REPROS THERAPEUTICS INC.  
(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction  
of incorporation)**

**001-15281  
(Commission File Number)**

**76-0233274  
(IRS Employer  
Identification No.)**

**2408 Timberloch Place, Suite B-7  
The Woodlands, Texas 77380  
(Address of principal executive offices and zip code)  
(281) 719-3400**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 8.01 OTHER EVENTS**

On August 6, 2009 Repros Therapeutics Inc. issued a press release titled Repros Therapeutics Inc. Announces That United States Food and Drug Administration Places Proellex® On Clinical Hold, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibits.

99.1 Press Release, dated August 6, 2009.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPROS THERAPEUTICS INC.**

Dated: August 6, 2009

By: /s/ Louis Ploth, Jr.  
Louis Ploth, Jr.  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release, dated August 6, 2009.